Losartan Potassium
Product Images NDC 71335-0972

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-0972). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713350972)

Losartan Potassium 100mg tablet label from Bryant Ranch Prepack. The label states it compares to Cozaar 100mg tablet and includes storage instructions to keep at 20°-25°C (68°-77°F). It shows a package quantity of 30 tablets and includes an NDC number 71335-0972. The label also has a barcode and warnings to keep drugs out of reach of children.*

FDA Label Image

Figure 1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows lower percentages for Losartan Potassium across a 66-month period, with an adjusted risk reduction of 13%, p=0.021.*

FDA Label Image

Figure 2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months from 0 to 66, and the y-axis represents the percentage of patients from 0 to 8%. Text indicates an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 shows a forest plot comparing primary endpoint events between Losartan Potassium and Atenolol across demographic subgroups, including age, gender, race, ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD). The plot displays event rates and hazard ratios with confidence intervals for both primary composite and stroke (fatal/non-fatal) outcomes, indicating relative treatment effects.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph showing the percentage of patients with events over 48 months, comparing Losartan Potassium (solid line) to placebo (dashed line). The graph notes a risk reduction of 16.1% with a p-value of 0.022, indicating a statistical comparison between the two groups over time.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium, showing the molecular arrangement including rings, functional groups, and potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.